title: ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.
abstract: The p53 tumor suppressor protein, a key regulator of cellular responses to genotoxic stress, is stabilized and activated after DNA damage. The rapid activation of p53 by ionizing radiation and radiomimetic agents is largely dependent on the ATM kinase. p53 is phosphorylated by ATM shortly after DNA damage, resulting in enhanced stability and activity of p53. The Mdm2 oncoprotein is a pivotal negative regulator of p53. In response to ionizing radiation and radiomimetic drugs, Mdm2 undergoes rapid ATM-dependent phosphorylation prior to p53 accumulation. This results in a decrease in its reactivity with the 2A10 monoclonal antibody. Phage display analysis identified a consensus 2A10 recognition sequence, possessing the core motif DYS. Unexpectedly, this motif appears twice within the human Mdm2 molecule, at positions corresponding to residues 258-260 and 393-395. Both putative 2A10 epitopes are highly conserved and encompass potential phosphorylation sites. Serine 395, residing within the carboxy-terminal 2A10 epitope, is the major target on Mdm2 for phosphorylation by ATM in vitro. Mutational analysis supports the conclusion that Mdm2 undergoes ATM-dependent phosphorylation on serine 395 in vivo in response to DNA damage. The data further suggests that phosphorylated Mdm2 may be less capable of promoting the nucleo-cytoplasmic shuttling of p53 and its subsequent degradation, thereby enabling p53 accumulation. Our findings imply that activation of p53 by DNA damage is achieved, in part, through attenuation of the p53-inhibitory potential of Mdm2.
authors.affiliation: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Maya
authors.forename: M
authors.initials: M
authors.lastname: Balass
authors.forename: S T
authors.initials: ST
authors.lastname: Kim
authors.forename: D
authors.initials: D
authors.lastname: Shkedy
authors.forename: J F
authors.initials: JF
authors.lastname: Leal
authors.forename: O
authors.initials: O
authors.lastname: Shifman
authors.forename: M
authors.initials: M
authors.lastname: Moas
authors.forename: T
authors.initials: T
authors.lastname: Buschmann
authors.forename: Z
authors.initials: Z
authors.lastname: Ronai
authors.forename: Y
authors.initials: Y
authors.lastname: Shiloh
authors.forename: M B
authors.initials: MB
authors.lastname: Kastan
authors.forename: E
authors.initials: E
authors.lastname: Katzir
authors.forename: M
authors.initials: M
authors.lastname: Oren
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001224:Aspartic Acid; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D004249:DNA Damage / Q000502:physiology* / Q000528:radiation effects; D004268:DNA-Binding Proteins; D018604:Epitope Mapping; D005347:Fibroblasts; D006801:Humans; D051379:Mice; D008845:Microinjections; D009154:Mutation; D009687:Nuclear Proteins; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D051736:Proto-Oncogene Proteins c-mdm2; D012694:Serine / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D025521:Tumor Suppressor Proteins
chemical_list: D000911:Antibodies, Monoclonal; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D001224:Aspartic Acid; D012694:Serine; C497206:MDM2 protein, human; C497207:Mdm2 protein, mouse; D051736:Proto-Oncogene Proteins c-mdm2; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; C576325:Atm protein, mouse; D017346:Protein Serine-Threonine Kinases